Last Updated: November 16, 2026

Investigational Drug Information for PF-06882961

« Back to Dashboard


What is the development status for investigational drug PF-06882961?

PF-06882961 is an investigational drug.

There have been 16 clinical trials for PF-06882961. The most recent clinical trial was a Phase 2 trial, which was initiated on March 13th 2025.

The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Obesity. The leading clinical trial sponsors are Pfizer and [disabled in preview].

There are forty-six US patents protecting this investigational drug and sixty-two international patents.

Recent Clinical Trials for PF-06882961
TitleSponsorPhase
Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or ObesityPfizerPHASE1
STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTSPfizerPhase 1
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes MellitusPfizerPhase 1

See all PF-06882961 clinical trials

Clinical Trial Summary for PF-06882961

Top disease conditions for PF-06882961
Top clinical trial sponsors for PF-06882961

See all PF-06882961 clinical trials

US Patents for PF-06882961

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PF-06882961 ⤷  Start Trial GLP-1 receptor agonists and uses thereof Pfizer Inc. (New York, NY) ⤷  Start Trial
PF-06882961 ⤷  Start Trial GLP-1 receptor agonists and uses thereof Pfizer Inc. (New York, NY) ⤷  Start Trial
PF-06882961 ⤷  Start Trial GLP-1R agonists and uses thereof QILU REGOR THERAPEUTICS INC. (Shanghai, CN) ⤷  Start Trial
PF-06882961 ⤷  Start Trial GLP-1 receptor agonists and uses thereof Pfizer Inc. (New York, NY) ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PF-06882961

Drugname Country Document Number Estimated Expiration Related US Patent
PF-06882961 Argentina AR110387 2036-12-16 ⤷  Start Trial
PF-06882961 Australia AU2017374860 2036-12-16 ⤷  Start Trial
PF-06882961 Brazil BR112019012211 2036-12-16 ⤷  Start Trial
PF-06882961 Canada CA2988721 2036-12-16 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

PF-06882961 Development Update and Market Projection

Last updated: October 11, 2026

PF-06882961, now known as danuglipron, is Pfizer's oral, non-peptide GLP-1 receptor agonist for type 2 diabetes and obesity. Pfizer discontinued the twice-daily formulation in late 2023 after liver-enzyme elevations emerged in clinical development, but continued work on a once-daily formulation. As of mid-2024, danuglipron remained an investigational asset with no FDA approval, no established launch date, and no Orange Book listing.

The commercial opportunity remains large because a successful oral GLP-1 could expand treatment beyond injectable semaglutide and tirzepatide. Danuglipron's risk profile, dose frequency, tolerability, and ability to match the weight-loss performance of competing oral candidates will determine whether it becomes a major product or a discontinued program.

What is PF-06882961 and how does danuglipron work?

Danuglipron is a small-molecule, non-peptide agonist of the human GLP-1 receptor. It is designed for oral administration and does not require the injection technology used by Ozempic, Wegovy, Mounjaro, and Zepbound.

GLP-1 receptor activation can:

  • Increase glucose-dependent insulin secretion.
  • Reduce glucagon secretion.
  • Slow gastric emptying.
  • Reduce appetite and food intake.
  • Improve glycemic control and body weight.

Danuglipron is pharmacologically distinct from oral semaglutide, which is a peptide requiring specialized absorption technology. Pfizer's small-molecule approach could reduce manufacturing complexity and potentially allow more convenient oral dosing, although clinical tolerability and exposure remain critical development challenges.

What is the current development status of PF-06882961?

Pfizer discontinued the twice-daily formulation of danuglipron in December 2023. The decision followed liver enzyme elevations observed in clinical studies. Pfizer said the program had not shown evidence of serious drug-induced liver injury, but the twice-daily formulation was not advanced because of the safety findings and the need to select an appropriate once-daily formulation. [1]

Pfizer continued evaluating a once-daily formulation. The company expected additional clinical data in 2024 and planned further development if the pharmacokinetic and safety profile supported progression. [1]

Development element Status
Active ingredient Danuglipron
Internal code PF-06882961
Modality Oral, non-peptide GLP-1 receptor agonist
Main target indications Type 2 diabetes and obesity
Twice-daily formulation Discontinued
Once-daily formulation Continued in development as of mid-2024
FDA approval None
Commercial launch None announced
Orange Book listing None because the product was not approved
Phase 3 status Not established as of mid-2024
Primary development risk Liver enzyme elevations, gastrointestinal tolerability, and efficacy relative to competing oral GLP-1 drugs

What clinical data support danuglipron?

Early and mid-stage clinical studies demonstrated glucose lowering and weight reduction, but the development record did not yet establish a competitive profile against approved injectable GLP-1 and GIP/GLP-1 medicines.

In a Phase 2 study in adults with type 2 diabetes, danuglipron reduced HbA1c and body weight compared with placebo. Gastrointestinal adverse events, including nausea and vomiting, were reported, consistent with the class. [2]

A separate Phase 2 obesity study evaluated multiple twice-daily doses. The trial supported biological activity and weight reduction, but the results did not eliminate concerns about dose frequency, tolerability, and liver chemistry. [3]

The key commercial question is not whether danuglipron activates GLP-1 receptors. It is whether a once-daily formulation can achieve:

  1. Clinically meaningful weight loss.
  2. Durable glycemic control.
  3. A safety profile without clinically important liver signals.
  4. Lower treatment burden than injectable products.
  5. Pricing acceptable to payers in a crowded GLP-1 market.

When could PF-06882961 reach the market?

A successful once-daily Phase 2 program would likely require a dose-selection study followed by large Phase 3 trials in obesity, type 2 diabetes, or both. A conventional development path would place a potential U.S. launch several years after successful Phase 3 initiation.

Milestone Earliest practical timing based on mid-2024 status
Once-daily formulation selection 2024
Dose-ranging or proof-of-concept studies 2024-2025
Phase 3 initiation 2025-2026
Regulatory filing 2027-2028
Potential U.S. approval 2028-2029
Broad commercial penetration 2029 onward

These dates are scenario estimates, not Pfizer guidance. A delay in dose selection, liver-safety monitoring, manufacturing scale-up, or Phase 3 recruitment could move approval beyond 2029. Failure to demonstrate an acceptable once-daily profile would eliminate the launch scenario.

How does danuglipron compare with oral semaglutide and orforglipron?

Danuglipron competes against both approved oral semaglutide and other investigational oral small-molecule GLP-1 receptor agonists.

Product Company Modality Status as of mid-2024 Strategic advantage
Rybelsus Novo Nordisk Oral semaglutide peptide FDA-approved for type 2 diabetes Established efficacy and regulatory approval
Danuglipron Pfizer Oral small-molecule GLP-1 agonist Clinical development Potentially simpler oral formulation
Orforglipron Eli Lilly Oral small-molecule GLP-1 agonist Late-stage clinical development Stronger late-stage positioning and obesity opportunity
Wegovy Novo Nordisk Injectable semaglutide FDA-approved for obesity Established weight-loss efficacy
Zepbound Eli Lilly Injectable tirzepatide FDA-approved for obesity High efficacy and strong commercial momentum

Orforglipron represented the most direct competitive threat because it used a similar non-peptide oral mechanism and had progressed further in clinical development. Eli Lilly reported positive Phase 2 obesity data for orforglipron, increasing the pressure on Pfizer to demonstrate a differentiated efficacy, safety, or dosing profile. [4]

Rybelsus has the advantage of an established label but requires administration under specific fasting conditions. A successful small-molecule oral GLP-1 could compete through simpler administration, manufacturing economics, or more flexible dosing.

What market could PF-06882961 address?

The addressable market includes type 2 diabetes, obesity, overweight patients with weight-related comorbidities, and potentially cardiovascular-risk reduction. Obesity is likely to be the larger commercial indication if danuglipron achieves weight loss approaching leading GLP-1 and GIP/GLP-1 therapies.

The market is expanding through:

  • Increased diagnosis of obesity as a chronic disease.
  • Broader reimbursement for anti-obesity medicines.
  • Greater use of GLP-1 medicines in patients without diabetes.
  • Demand for oral alternatives to injections.
  • Expansion into cardiovascular, renal, sleep apnea, and metabolic indications.

Novo Nordisk and Eli Lilly have reported rapid growth in their GLP-1 franchises, confirming substantial demand but also exposing the competitive barriers. Manufacturing capacity, payer restrictions, prior authorization, supply availability, and long-term adherence remain material commercial constraints. [5][6]

PF-06882961 revenue projection

The following estimates represent scenario-based peak annual sales for danuglipron, assuming a U.S. launch followed by international expansion.

Scenario Commercial assumptions Estimated peak annual sales
Failure Once-daily formulation does not overcome safety or tolerability issues $0
Low case Approval limited to type 2 diabetes; modest efficacy and reimbursement $0.5-$1.5 billion
Base case Approval in diabetes and obesity; competitive oral profile; gradual payer access $2-$4 billion
High case Strong weight-loss efficacy, good tolerability, broad access, global launch $5-$8 billion

The base case requires Pfizer to solve the issues that affected the twice-daily formulation. An oral product that produces materially less weight loss than injectable semaglutide or tirzepatide could be commercially relevant but still limited to patients prioritizing oral administration.

Pfizer's existing commercial infrastructure could support a large launch, but the company would face a significant execution challenge. The GLP-1 market is concentrated around Novo Nordisk and Eli Lilly, both of which have established prescriber relationships, manufacturing scale, clinical outcomes data, and payer negotiations.

What patents protect PF-06882961?

Danuglipron is expected to be protected by a combination of patent families covering the active compound, pharmaceutical compositions, methods of treatment, solid forms, salts, formulations, and manufacturing processes.

A definitive public patent-expiration analysis requires review of the relevant worldwide patent families, continuations, national-stage filings, terminal disclaimers, patent-term adjustment, and any patent-term extension. The development code alone does not identify every applicable patent or establish the enforceable expiry date.

The likely protection structure is:

Protection category Commercial role
Composition-of-matter patents Core protection for danuglipron and related chemical genus claims
Salt and solid-form patents Protection against alternative crystalline or salt forms
Formulation patents Protection for oral dosage forms, modified release, and stability
Method-of-use patents Protection for diabetes, obesity, weight reduction, or comorbidity treatment
Manufacturing patents Protection for synthesis, intermediates, purification, and scale-up
Combination patents Potential protection for use with other metabolic therapies

Patent applications for the active compound were likely filed years before public clinical development, so a nominal 20-year term from the earliest nonprovisional priority filing could place core composition protection in the late 2030s. That is an estimate rather than a verified expiration date. Patent-term adjustment, patent-term extension, continuations, and jurisdiction-specific prosecution could change the effective protection period.

What is the Orange Book status of danuglipron?

Danuglipron has no Orange Book listing because it has not received FDA approval. Orange Book patent listings generally become relevant after an approved drug application is submitted and the sponsor identifies patents that claim the drug substance, drug product, or approved method of use.

If approved, Pfizer could seek Orange Book listing for eligible patents covering:

  • The active ingredient.
  • Approved tablets or capsules.
  • Specific dosage regimens.
  • Approved obesity or diabetes methods of use.

A future generic applicant could challenge listed patents through an Abbreviated New Drug Application and a Paragraph IV certification. No Paragraph IV challenge or ANDA litigation could be confirmed before FDA approval and Orange Book listing.

What regulatory exclusivity could danuglipron receive?

If approved for obesity or type 2 diabetes, danuglipron would receive FDA new chemical entity exclusivity if it qualifies as a new active moiety. NCE exclusivity generally lasts five years and restricts submission of certain abbreviated applications during the initial period. [7]

Potential regulatory protections include:

Protection Potential duration or effect
New chemical entity exclusivity Five years, if eligibility requirements are met
Orphan-drug exclusivity Seven years only for an approved orphan indication
Pediatric exclusivity Six additional months if FDA requirements are satisfied
Patent-term extension Up to five years for an eligible patent, subject to statutory limits
Three-year clinical-investigation exclusivity Possible for certain new indications or dosage forms

Regulatory exclusivity would be separate from patent rights. The commercial duration would depend on the interaction between patent expiry, regulatory exclusivity, formulation patents, method-of-use patents, and generic litigation.

What generic-entry risks exist for PF-06882961?

Generic entry would likely occur in stages rather than through a single loss-of-exclusivity event.

The primary risks are:

  1. Paragraph IV challenges to core compound or formulation patents.
  2. Generic tablets that avoid narrower formulation claims.
  3. Method-of-use litigation involving diabetes and obesity labels.
  4. Authorized-generic competition by Pfizer.
  5. Patent settlement agreements that permit a defined generic entry date.
  6. Competing oral GLP-1 drugs eroding sales before patent expiry.

The greatest risk may arise before generic entry. Orforglipron, oral semaglutide, and other oral metabolic drugs could reduce the value of danuglipron by establishing stronger efficacy or better dosing convenience.

What litigation and settlement agreements affect danuglipron?

No major publicly reported patent litigation or settlement agreement involving danuglipron had been established as of mid-2024. The principal legal risk was prospective: future patent challenges after approval, Orange Book listing, and generic filing.

Pfizer has faced broader strategic pressure in the obesity-drug market after discontinuing other metabolic candidates, including lotiglipron. Danuglipron's development therefore carried portfolio-level importance, but no publicly disclosed settlement or licensing transaction transferred the program to another company as of the stated period.

How strong is the PF-06882961 patent estate?

The patent estate is strategically valuable if it contains a durable composition-of-matter patent and enforceable formulation claims. Its strength cannot be inferred from the number of published applications alone.

The strongest protection would come from:

  • A valid composition patent with claims difficult to design around.
  • Multiple independent patent families with staggered expiry dates.
  • Stable and commercially practical oral formulations.
  • Manufacturing claims that cover efficient large-scale synthesis.
  • Approved method-of-use claims aligned with the highest-value indications.

The estate would be weaker if the core compound patent expires before the product reaches market, if formulation claims are narrow, or if competing small molecules can avoid the claimed chemical genus.

What are the main launch scenarios for PF-06882961?

Successful once-daily development

Pfizer demonstrates acceptable liver safety, clinically meaningful weight loss, and tolerability. The company advances to Phase 3 and targets obesity and type 2 diabetes. This is the $2-$4 billion base-case opportunity.

Diabetes-focused approval

The product reaches the market with a type 2 diabetes indication but shows limited obesity efficacy or tolerability. Revenue could remain below the leading injectable products, with use concentrated among patients seeking an oral option.

Delayed development

Pfizer requires additional formulation work or extended liver-safety monitoring. A launch shifts beyond 2029, reducing commercial value and allowing oral competitors to establish market share.

Program discontinuation

Recurrent liver-enzyme elevations or inadequate efficacy prevent advancement. Under this scenario, danuglipron produces no product revenue and Pfizer's development expenditure becomes a sunk cost.

Key Takeaways

  • PF-06882961, or danuglipron, is Pfizer's oral, non-peptide GLP-1 receptor agonist.
  • Pfizer discontinued the twice-daily formulation after liver-enzyme elevations but continued work on a once-daily formulation as of mid-2024.
  • The product had no FDA approval, Orange Book listing, Paragraph IV litigation, or announced launch date.
  • A successful once-daily formulation could target a multibillion-dollar obesity and diabetes market.
  • A practical launch window was approximately 2028-2029, assuming successful Phase 2 and Phase 3 development.
  • The base-case peak-sales opportunity is approximately $2-$4 billion, with downside risk to zero and upside potential above $5 billion.
  • Orforglipron, oral semaglutide, tirzepatide, and injectable semaglutide are the principal competitive threats.
  • The most important value drivers are liver safety, weight-loss efficacy, dosing convenience, manufacturing cost, payer access, and composition-of-matter patent duration.

FAQs

Is PF-06882961 the same as danuglipron?

Yes. PF-06882961 is Pfizer's development code for danuglipron, an oral small-molecule GLP-1 receptor agonist.

Did Pfizer discontinue danuglipron?

Pfizer discontinued the twice-daily formulation in late 2023. The company continued evaluating a once-daily formulation as of mid-2024.

Is danuglipron approved for weight loss?

No. Danuglipron had no FDA approval for obesity, overweight, or type 2 diabetes as of mid-2024.

Could danuglipron compete with oral semaglutide?

Yes, if Pfizer can demonstrate comparable efficacy, acceptable liver safety, lower administration burden, and competitive pricing. Oral semaglutide has the advantage of existing FDA approval and commercial adoption.

What is the biggest investment risk for danuglipron?

The largest risk is that the once-daily formulation will not provide a sufficient combination of liver safety, gastrointestinal tolerability, and weight-loss efficacy to justify Phase 3 development and commercial launch.

References

  1. Pfizer Inc. (2023, December 1). Pfizer updates development plans for twice-daily danuglipron. Pfizer Investor Relations.

  2. Pfizer Inc. (2022). Pfizer presents positive Phase 2 results for oral GLP-1 receptor agonist danuglipron in adults with type 2 diabetes. Pfizer Newsroom.

  3. ClinicalTrials.gov. (2023). A study of danuglipron in participants with obesity. U.S. National Library of Medicine.

  4. Eli Lilly and Company. (2023). Lilly's oral GLP-1 receptor agonist orforglipron demonstrates significant weight loss in Phase 2 study. Lilly Investor Relations.

  5. Novo Nordisk A/S. (2024). Annual report 2023. Novo Nordisk.

  6. Eli Lilly and Company. (2024). Annual report 2023. Eli Lilly and Company.

  7. U.S. Food and Drug Administration. (2024). Small business assistance: Frequently asked questions on the patent term restoration and extension provisions. FDA.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.